Cargando…
Temporal Association Between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis: A Case Report and Literature Review
With the recent approval and widespread administration of the Pfizer-BioNTech, Moderna, and Janssen vaccines worldwide, incidence of severe Coronavirus Disease 2019 (COVID-19) infection has significantly decreased. In spite of their undisputed role in reducing the severity of the disease and reducti...
Autores principales: | Sulemankhil, Imran, Abdelrahman, Mohammad, Negi, Smita I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364889/ https://www.ncbi.nlm.nih.gov/pubmed/34420869 http://dx.doi.org/10.1016/j.carrev.2021.08.012 |
Ejemplares similares
-
Ad26.cov2-s: Myocarditis: case report
Publicado: (2021) -
Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination
por: Ujueta, Francisco, et al.
Publicado: (2021) -
Ad26.COV2-S/elasomeran/tozinameran: Myocarditis: 7 case reports
Publicado: (2022) -
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report
por: Naghashzadeh, Farah, et al.
Publicado: (2022)